BRIEF—Ribonexus appoints new chief development officer

French biotech company Ribonexus has announced the appointment of David Howat as its new chief development officer ahead of advancing its lead product into preclinical development.

With over 30 years of experience in R&D, Dr Howat has been responsible for multiple regulatory filings and Phase I and II programs for several companies. Previously, he held CDO positions at Haoma Medica and Evgen Pharma.

Ribonexus is focused on developing drugs targeting eukaryotic initiation factor-4A (eIF4A), which is highly active in a variety of solid and hematological cancers and whose activity is associated with resistance to many current therapies.